{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:48:29Z","timestamp":1789213709506,"version":"build-2803163510"},"reference-count":126,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["GACR19-01417S"],"award-info":[{"award-number":["GACR19-01417S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Czech Health Research Council","doi-asserted-by":"publisher","award":["AZV NU21-03-00386"],"award-info":[{"award-number":["AZV NU21-03-00386"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["Center of Excellence UNCE\/MED\/016"],"award-info":[{"award-number":["Center of Excellence UNCE\/MED\/016"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody\u2013drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of \u201cold\u201d cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas are based on nuclear imaging, namely PET. A theranostic approach that combines diagnostic or restaging lymphoma imaging with targeted treatment represents an appealing innovative strategy in personalized medicine. The future of theranostics will require not only the capability to provide suitable disease-specific molecular probes but also expertise on big data processing and evaluation. Here, we review the concept of targeted drug delivery in malignant lymphomas from RIT and ADC to a wide array of passively and actively targeted nano-sized investigational agents. We also discuss the future of molecular imaging with special focus on monoclonal antibody-based and monoclonal antibody-derived theranostic strategies.<\/jats:p>","DOI":"10.3390\/cancers14030626","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:02:53Z","timestamp":1643194973000},"page":"626","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5908-5182","authenticated-orcid":false,"given":"Tomas","family":"Etrych","sequence":"first","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-6502","authenticated-orcid":false,"given":"Alena","family":"Braunova","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-1667","authenticated-orcid":false,"given":"David","family":"Zogala","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Radiology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4397-9469","authenticated-orcid":false,"given":"Nicol","family":"Renesova","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic"},{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","article-title":"Pathogenesis of non-Hodgkin\u2019s lymphoma","volume":"29","author":"Nogai","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2019.08.019","article-title":"As the world turns, evolving lymphoma classifications-past, present and future","volume":"95","author":"Swerdlow","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tong, J.T.W., Harris, P.W.R., Brimble, M.A., and Kavianinia, I. (2021). An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 26.","DOI":"10.3390\/molecules26195847"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jin, Y., Schladetsch, M.A., Huang, X., Balunas, M.J., and Wiemer, A.J. (2021). Stepping forward in antibody-drug conjugate development. Pharmacol. Ther., 229.","DOI":"10.1016\/j.pharmthera.2021.107917"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/mp500762u","article-title":"Recent advances in the development of new auristatins: Structural modifications and application in antibody drug conjugates","volume":"12","author":"Maderna","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_29","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: First Global Approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: Outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tilly, H., Morschhauser, F., Sehn, L.H., Friedberg, J.W., Trn\u011bn\u00fd, M., Sharman, J.P., Herbaux, C., Burke, J.M., Matasar, M., and Rai, S. (2021). Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2115304"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(21)00191-1","article-title":"The era of CD19-directed therapy in diffuse large B-cell lymphoma","volume":"22","author":"Maddocks","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_45","first-page":"1","article-title":"The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point","volume":"40","author":"Tolcher","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_46","first-page":"67","article-title":"Proteases as activators for cytotoxic prodrugs in antitumor therapy","volume":"11","author":"Weidle","year":"2014","journal-title":"Cancer Genom. Proteom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-17-0219","article-title":"Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates","volume":"23","author":"Hinrichs","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Desnoyers, L.R., Vasiljeva, O., Richardson, J.H., Yang, A., Menendez, E.E., Liang, T.W., Wong, C., Bessette, P.H., Kamath, K., and Moore, S.J. (2013). Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3006682"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1535-7163.MCT-20-0183","article-title":"The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2\/NaPi2b","volume":"20","author":"Bodyak","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/bloodadvances.2020003276","article-title":"The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab Pasudotox: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_58","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60327-360-2_1","article-title":"Current trends in liposome research","volume":"605","author":"Elbayoumi","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","article-title":"Nanomedicines for the treatment of hematological malignancies","volume":"287","author":"Deshantri","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1021\/bc970184f","article-title":"Stabilization of substances in circulation","volume":"9","author":"Monfardini","year":"1998","journal-title":"Bioconjug. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Olusanya, T.O.B., Haj Ahmad, R.R., Ibegbu, D.M., Smith, J.R., and Elkordy, A.A. (2018). Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules, 23.","DOI":"10.3390\/molecules23040907"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/nnm.10.152","article-title":"Doxorubicin variants for hematological malignancies","volume":"6","author":"Visani","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Houshmand, M., Garello, F., Circosta, P., Stefania, R., Aime, S., Saglio, G., and Giachino, C. (2020). Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials, 10.","DOI":"10.3390\/nano10020276"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., and Hua, S. (2015). Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00286"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","article-title":"Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory landscape","volume":"23","author":"Zylberberg","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2017.04.006","article-title":"Dual-functional drug liposomes in treatment of resistant cancers","volume":"115","author":"Mu","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1385\/MO:19:1:55","article-title":"Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma","volume":"19","author":"Neri","year":"2002","journal-title":"Med. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: Focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Visco, C., Pregnolato, F., Ferrarini, I., De Marco, B., Bonuomo, V., Sbis\u00e0, E., Fraenza, C., Bernardelli, A., Tanasi, I., and Quaglia, F.M. (2021). Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Crit. Rev. Oncol. Hematol., 163.","DOI":"10.1016\/j.critrevonc.2021.103377"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u226560 years: Results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"Sancho","year":"2021","journal-title":"Cancer Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","article-title":"Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie AGMT](NHL-14)","volume":"58","author":"Fridrik","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-20-0514","article-title":"Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed\/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial","volume":"26","author":"Mei","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-19-2152","article-title":"Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1080\/10428194.2020.1775206","article-title":"New tricks for old drugs: Combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed\/refractory diffuse large B cell lymphoma","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clml.2013.09.009","article-title":"Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy","volume":"14","author":"Kaplan","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12446","article-title":"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(\u00ae) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas","volume":"162","author":"Hagemeister","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17425247.2018.1517747","article-title":"Clinical translation of immunoliposomes for cancer therapy: Recent perspectives","volume":"15","author":"Wang","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2018.02.015","article-title":"Immunoliposomes in clinical oncology: State of the art and future perspectives","volume":"275","author":"Merino","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sun, H., Zhu, X., Lu, P.Y., Rosato, R.R., Tan, W., and Zu, Y. (2014). Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids, 3.","DOI":"10.1038\/mtna.2014.32"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2009.02.010","article-title":"PEG conjugates in clinical development or use as anticancer agents: An overview","volume":"61","author":"Pasut","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","article-title":"State of the art in PEGylation: The great versatility achieved after forty years of research","volume":"161","author":"Pasut","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/bc200049d","article-title":"Polyoxazoline: Chemistry, properties, and applications in drug delivery","volume":"22","author":"Viegas","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"22316","DOI":"10.18632\/oncotarget.24806","article-title":"Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment","volume":"9","author":"Hoelzer","year":"2018","journal-title":"Oncotarget"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Zahoranov\u00e1, A., and Luxenhofer, R. (2021). Poly(2-oxazoline)- and Poly(2-oxazine)-Based Self-Assemblies, Polyplexes, and Drug Nanoformulations-An Update. Adv. Healthc. Mater., 10.","DOI":"10.1002\/adhm.202001382"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","article-title":"Polymer nanomedicines","volume":"156","author":"Yang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chytil, P., Kostka, L., and Etrych, T. (2021). HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery. J. Pers. Med., 11.","DOI":"10.3390\/jpm11020115"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2020.08.042","article-title":"Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab","volume":"328","author":"Klener","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2018.09.018","article-title":"Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging","volume":"289","author":"Etrych","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11019-019-09898-3","article-title":"Theranostics: Is it really a revolution? Evaluating a new term in medicine","volume":"22","author":"Wiesing","year":"2019","journal-title":"Med. Health Care Philos."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jcem-9-11-1122","article-title":"Radioiodine therapy of metastases from carcinoma of the thyroid; a 6-year progress report","volume":"9","author":"Seidlin","year":"1949","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-11-5-492","article-title":"The scintillation counter in clinical studies of human thyroid physiology using I131","volume":"11","author":"Allen","year":"1951","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Morris, M.J., Bono, J.S.D., Chi, K.N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S.T., Nordquist, L.T., Vaishampayan, N., and El-Haddad, G. (2021). Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2967\/jnumed.121.262710","article-title":"(177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine","volume":"62","author":"Czernin","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kang, L., Li, C., Rosenkrans, Z.T., Huo, N., Chen, Z., Ehlerding, E.B., Huo, Y., Ferreira, C.A., Barnhart, T.E., and Engle, J.W. (2021). CD38-Targeted Theranostics of Lymphoma with (89)Zr\/(177)Lu-Labeled Daratumumab. Adv. Sci., 8.","DOI":"10.1002\/advs.202001879"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.beha.2012.04.004","article-title":"Radioimmunotherapy in mantle cell lymphoma","volume":"25","author":"Skarbnik","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2017-12-819011","article-title":"CD38 pretargeted RIT of B-cell tumors","volume":"131","author":"Buchsbaum","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Dun, Y., Huang, G., Liu, J., and Wei, W. (2021). ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discov. Today.","DOI":"10.1016\/j.drudis.2021.11.019"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, Design, and Applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/S2352-3026(20)30065-X","article-title":"Molecular imaging in lymphoma beyond (18)F-FDG-PET: Understanding the biology and its implications for diagnostics and therapy","volume":"7","author":"Kahle","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: Impact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma","volume":"60","author":"Lapa","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_118","first-page":"334","article-title":"A pilot study treatment of malignant tumors using low-dose (18)F-fluorodeoxyglucose ((18)F-FDG)","volume":"10","author":"Paul","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7150\/thno.48811","article-title":"MRI-traceable theranostic nanoparticles for targeted cancer treatment","volume":"11","author":"Anani","year":"2021","journal-title":"Theranostics"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/acs.nanolett.8b04411","article-title":"Dynamically Reversible Iron Oxide Nanoparticle Assemblies for Targeted Amplification of T1-Weighted Magnetic Resonance Imaging of Tumors","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.7150\/thno.59096","article-title":"Improving the sensitivity of T (1) contrast-enhanced MRI and sensitive diagnosing tumors with ultralow doses of MnO octahedrons","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.2147\/IJN.S218085","article-title":"Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy","volume":"14","author":"Cai","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2013.01.029","article-title":"Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs","volume":"167","author":"Howell","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"31114","DOI":"10.1021\/acsami.8b11408","article-title":"Effective pH-Activated Theranostic Platform for Synchronous Magnetic Resonance Imaging Diagnosis and Chemotherapy","volume":"10","author":"Wang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(14)70021-X","article-title":"Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET\/CT scans for children and young adults with cancer: A prospective, non-randomised, single-centre study","volume":"15","author":"Klenk","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.actbio.2019.11.027","article-title":"Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy","volume":"102","author":"Zhi","year":"2020","journal-title":"Acta Biomater."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/626\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:30Z","timestamp":1760134110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":126,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030626"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030626","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}